



Ad hoc announcement pursuant to article 53 LR of the SIX Swiss Exchange


DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors

Dottikon, Switzerland, July 7, 2023 – The shareholders approved all proposals of the Board of Directors at the 18th Annual General Meeting of Dottikon ES Holding AG in Baden. At the beginning of the Annual General Meeting, the 198 present shareholders represented 12'543'345 voting rights and therefore 94.5% of the total of 13'267'547 registered shares with voting rights.

The Annual Report, the financial statements 2022/23, and the Group financial statements 2022/23 of Dottikon ES Holding AG were approved by the Annual General Meeting. The Compensation Report 2022/23 was approved in a consultative voting by the Annual General Meeting. Discharge for the business year 2022/23 was granted to the responsible members of the Board of Directors and Senior Management. The proposal of the Board of Directors to carry forward the entire retained earnings to new account and to pay no dividend was accepted. The previous Chairman of the Board of Directors Dr. Markus Blocher was confirmed for another one-year term. In addition, Dr. Alfred Scheidegger was reelected for a one-year term as Deputy Chairman and Dr. Bernhard Urwyler as member of the Board. All three Board members were reelected for a term of one year as members of the Compensation Committee. Dr. Markus Blocher was elected as its Chairman and Dr. Alfred Scheidegger as Deputy Chairman. The proposed maximum amounts of prospective remunerations for the Board of Directors and Senior Management, respectively, were approved. KPMG AG, Zug, was reelected as external auditor for another one-year term. Dr. iur. Michael Wicki, attorney-at-law and notary public, was reelected as independent proxy until and for the 19th Annual General Meeting.

DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 110 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, as well as reduce energy consumption, waste, and CO₂ emissions sustainably. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development and management, clear and transparent data and process documentation, and close customer communication.



dottikon

Dottikon ES Holding AG is listed on the SIX Swiss Exchange.

Symbol: DESN

Security number: 58258171

ISIN: CH0582581713

For further information, please contact

Markus Blocher, Ph.D.

CEO

Dottikon ES Holding AG

Tel +41 56 616 82 01

investor-relations@dottikon.com



dottikon

Voting results

Agenda item	Present voting rights	Approval	Rejection	Abstention
1. Approval of Annual Report, financial statements 2022/23 and Group financial statements 2022/23 of Dottikon ES Holding AG	12'543'345	100.0%	0.0%	0.0%
2. Compensation Report 2022/23: Consultative voting	12'529'955	95.5%	4.4%	0.1%
3. Discharge for the business year 2022/23 to the members of the Board of Directors and Senior Management	11'256'884	99.5%	0.4%	0.1%
4. Appropriation of retained earnings 2022/23	12'529'955	99.9%	0.1%	0.0%
5. Election of the Board of Directors				
5.1 Dr. Markus Blocher as Chairman of the Board of Directors	12'529'955	95.9%	4.1%	0.0%
5.2 Dr. Alfred Scheidegger as Deputy Chairman of the Board of Directors	12'529'955	98.1%	1.9%	0.0%
5.3 Dr. Bernhard Urwyler as member of the Board of Directors	12'529'955	98.6%	1.4%	0.0%
6. Election of the Compensation Committee				
6.1 Dr. Markus Blocher as Chairman of the Compensation Committee	12'529'955	94.9%	5.0%	0.1%
6.2 Dr. Alfred Scheidegger as Deputy Chairman of the Compensation Committee	12'529'955	96.3%	3.6%	0.1%
6.3 Dr. Bernhard Urwyler as member of the Compensation Committee	12'529'955	97.6%	2.3%	0.1%
7. Approval of the proposed maximum amounts of prospective remunerations for the Board of Directors	12'529'955	99.4%	0.5%	0.1%
8. Approval of the proposed maximum amounts of prospective remunerations for Senior Management	12'529'955	98.9%	0.9%	0.2%
9. Election of external auditor KPMG AG, Zug	12'529'955	99.8%	0.1%	0.1%
10. Election of independent proxy Dr. iur. Michael Wicki	12'529'955	99.9%	0.1%	0.0%